RT Journal Article
SR Electronic
T1 Protein-truncating and rare missense variants in <em>ATM</em> and <em>CHEK2</em> and associations with cancer in UK Biobank whole-exome sequenced data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.01.24309756
DO 10.1101/2024.07.01.24309756
A1 Mukhtar, Toqir K.
A1 Wilcox, Naomi
A1 Dennis, Joe
A1 Yang, Xin
A1 Naven, Marc
A1 Mavaddat, Nasim
A1 Perry, John R. B.
A1 Gardner, Eugene J.
A1 Easton, Douglas F.
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.07.01.24309756.abstract
AB Background Deleterious germline variants in ATM and CHEK2 have been associated with a moderately increased risk of breast cancer. Risks for other cancers remain unclear, and require further investigation.Methods Cancer associations for coding variants in ATM and CHEK2 were evaluated using whole-exome sequenced data from UK Biobank linked to cancer registration data (348,488 participants), and analysed both as a retrospective case-control and a prospective cohort study. Odds ratios, hazard ratios, and combined relative risks (RRs) were estimated by cancer type and gene. Separate analyses were performed for protein-truncating variants (PTVs) and rare missense variants (rMSVs; allele frequency &lt;0·1%).Results PTVs in ATM were associated with increased risks of nine cancers at p&lt;0·001 (pancreas, oesophagus, lung, melanoma, breast, ovary, prostate, bladder, lymphoid leukaemia [LL]), and two at p&lt;0·05 (colon, diffuse non-Hodgkin’s lymphoma [DNHL]). Carriers of rMSVs had increased risks of four cancers (p&lt;0·05: stomach, pancreas, prostate, Hodgkin’s disease [HD]). RRs were highest for breast, prostate, and any cancer where rMSVs lay in the FAT or PIK domains, and had a CADD score in the highest quintile.PTVs in CHEK2 were associated with three cancers at p&lt;0·001 (breast, prostate, HD), and six at p&lt;0·05 (oesophagus, melanoma, ovary, kidney, DNHL, myeloid leukaemia). Carriers of rMSVs had increased risks of five cancers (p&lt;0·001: breast, prostate, LL; p&lt;0·05: melanoma, multiple myeloma).Conclusion PTVs in ATM and CHEK2 are associated with a wide range of cancers, with the highest RR for pancreatic cancer in ATM PTV carriers. These findings can inform genetic counselling of carriers.WHAT IS ALREADY KNOWN ON THIS TOPICWhile previous research shows there is evidence for association between variants in ATM or CHEK2 and multiple cancer types in individual smaller studies, the associations have not been consistently evaluated across all cancer types and, with the exception of breast cancer, the strengths of association are unclear.WHAT THIS STUDY ADDSWe examined data from a large cohort study to derive relative and absolute risks for all cancer types for carriers of PTVs and rMSVs in CHEK2 and ATM .ATM PTVs were associated with significantly increased risk for 11 of 23 sites examined (nine at p&lt;0·001), with the relative risk being highest for pancreatic cancer (approximately seven-fold). Carriers of rMSVs had increased risks of four cancers, with a RR of approximately 1·5.For CHEK2 PTVs, statistically significant risks were observed for seven of the 21 sites examined (one at p&lt;0·001). Carriers of rMSVs had increased risks of five cancers with the risk being highest for lymphoid leukaemia (approximately two-fold).HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICYATM and CHEK2 are included on many cancer gene panels used in family cancer clinics, and the risk estimates from these analyses can inform genetic counselling for carriers.The estimated absolute risks for pancreatic cancer in ATM PTV carriers (11% in males and 8% in females by age 85) are notably higher than for other major pancreatic susceptibility genes including BRCA2, CDK2NA, and PALB2. Our findings can also inform NICE guidelines for pancreatic cancer, which do not currently include ATM .Competing Interest StatementDFE is listed as a creator of the BOADICEA model which has been licensed by Cambridge Enterprise, University of Cambridge. EJG and JRBP hold shares in, and are employees of, Insmed Inc. All other authors declare no competing interests.Funding StatementThis work has been funded by European Union's Horizon 2020 Research and Innovation Program (BRIDGES grant 634935), Wellcome Trust (grant v203477/Z/16/Z), Cancer Research UK grant (PPRPGM-Nov20\100002), and the Medical Research Council (unit program: MC_UU_12015/2,MC_UU_00006/2). This work was also supported by core funding from the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. NW was supported by the International Alliance for Cancer Early Detection, an alliance between Cancer Research UK (C14478/A29329), Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London, and the University of Manchester. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC). Research Ethics Committee reference 11/NW/0382). This research has been conducted using the UK Biobank Resource under Application Number 28126.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRequests for access to UK Biobank data should be made to the UK Biobank Access Management Team (access{at}ukbiobank.ac.uk).